2543 Weekly cabazitaxel in “unfit” metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. CABASEM-SOGUG phase II trial
Fernandez Parra, E.M, Ochoa, M, Castellano, D, Munielo, L, Juan, M.J, Perez Valderrama, B, Mellado, B, Fernandez Calvo, O, Anido, U, Domenech, M, Hernando, S, Arranz, J.A, Caballero, C, Campayo, M, Estevez, P, Leon, L, Climent, M.A
Published in European journal of cancer (1990) (01.09.2015)
Published in European journal of cancer (1990) (01.09.2015)
Get full text
Journal Article
Phase II study of weekly cabazitaxel for ‘unfit’ metastatic castration resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment. Circulating tumour cell (CTC) analysis (SOGUG-CABASEM Trial)
Anido, U., Fita, M.J. Juan, Munielo-Romay, L., Pérez-Valderrama, B., Mellado, B., de Olza, M. Ochoa, Calvo, O. Fernandez, Castellano, D., Parra, E.M. Fernandez, Domenec, M., Hernando, S., Arija, J. Arranz, Caballero, C., Duran, I., Campayo, M., Climent, M.A.
Published in Annals of oncology (01.10.2016)
Published in Annals of oncology (01.10.2016)
Get full text
Journal Article